The Patent Finder

Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds

Revance Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 61/623,087, filed Apr 12, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,857,215Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
In force
 · High confidence
UsedRemaining
Revance Therapeutics, Inc.In forceHigh confidence
US 9,393,291Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
In force
 · High confidence
Revance Therapeutics, Inc.In forceHigh confidence
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited